Effect of 3-month Treatment With F2695 (75mg OD) on Improving Functional Recovery of Patients With Ischemic Stroke. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study
Phase of Trial: Phase III
Latest Information Update: 25 Oct 2019
Price : $35 *
At a glance
- Drugs Levomilnacipran (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms LIFE
- Sponsors Pierre Fabre
- 31 Mar 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 18 Nov 2014 Planned End Date changed from 1 Jan 2015 to 1 Feb 2015, according to ClinicalTrials.gov record.
- 18 Nov 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Feb 2015, according to ClinicalTrials.gov record.